KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $292,598.28 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 10,926 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $292,598.28. Following the sale, the chief executive officer owned 479,989 shares in the company, valued at $12,854,105.42. This represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV traded up $0.02 during mid-day trading on Tuesday, hitting $26.81. 8,068,030 shares of the company’s stock traded hands, compared to its average volume of 7,414,539. The company’s 50-day moving average is $21.74 and its two-hundred day moving average is $17.54. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10. The company has a market capitalization of $1.43 billion, a P/E ratio of -7.75 and a beta of -0.12. KalVista Pharmaceuticals, Inc. has a 1 year low of $9.83 and a 1 year high of $26.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $39.17 million for the quarter, compared to analysts’ expectations of $39.03 million. On average, equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KALV has been the topic of several analyst reports. Leerink Partners downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. JonesTrading downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Needham & Company LLC downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Finally, Stifel Nicolaus upped their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $30.60.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its stake in KalVista Pharmaceuticals by 42.5% in the 1st quarter. Bank of America Corp DE now owns 555,628 shares of the specialty pharmaceutical company’s stock worth $11,185,000 after acquiring an additional 165,815 shares in the last quarter. Royal Bank of Canada grew its stake in KalVista Pharmaceuticals by 137.0% in the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock worth $59,000 after acquiring an additional 1,686 shares in the last quarter. Elmind Capital LP grew its stake in KalVista Pharmaceuticals by 27.5% in the 1st quarter. Elmind Capital LP now owns 1,021,300 shares of the specialty pharmaceutical company’s stock worth $20,559,000 after acquiring an additional 220,000 shares in the last quarter. Quantinno Capital Management LP grew its stake in KalVista Pharmaceuticals by 11.3% in the 1st quarter. Quantinno Capital Management LP now owns 32,453 shares of the specialty pharmaceutical company’s stock worth $653,000 after acquiring an additional 3,297 shares in the last quarter. Finally, Octagon Capital Advisors LP grew its stake in KalVista Pharmaceuticals by 13.9% in the 1st quarter. Octagon Capital Advisors LP now owns 1,450,000 shares of the specialty pharmaceutical company’s stock worth $29,188,000 after acquiring an additional 176,667 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.